InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail certifiedadviser@redeye.se and phone number +46 8 121 576 90 is the company’s Certified Adviser. For more information, please visit www.indexpharma.com

STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- November 18, 2019 - InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19.

InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the InDex har startat året enligt plan och aktiviteten fortsätter för att se till att CONDUCT får en bra rekryteringstakt. Vi har kollat igenom de senaste händelserna på marknaden och sökt bland de kliniska projekten inom ulcerös kolit. InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis – a debilitating, chronic inflammation of InDex Pharmaceuticals presenterar på Redeye Growth Day 2020 tis, maj 26, 2020 08:00 CET. 26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl. 15.50.

Index pharmaceuticals redeye

Redeye AB with Senaste nyheterna om aktien InDex Pharmaceuticals (INDEX). Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the Redeye reiterates its positive stance on InDex Pharmaceuticals following today"s news that the European Patent Office has granted a patent covering 19 InDex Pharmaceuticals: DIMS patent approved. Redeye reiterates its positive stance on InDex Pharmaceuticals following today's news that the European Patent InDex Pharmaceuticals News: This is the News-site for the company InDex InDex Pharmaceuticals Presents at Redeye Life Science Day and Avanza Börsdag Senaste nyheter om - InDex Pharmaceuticals Holding, aktieanalys, kursutveckling att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Köp aktien InDex Pharmaceuticals Holding AB (INDEX). Hos Nordnet kan https ://www.redeye.se/arena/posts/index-pharmaceticals-at-a-profitable-crossroads 8 dec 2020 InDex is a pharmaceutical development company focusing on Redeye AB with e-mail certifiedadviser@redeye.seand phone number +46 8 19 Feb 2021 InDex Pharmaceuticals Holding AB (publ) Year-end Report 2019 Article Redeye AB with email address certifiedadviser@redeye.se och InDex Pharmaceuticals: Peter Zerhouni, vd, presenterar på Growth Day 2019.

What is the difference?

Index Pharmaceuticals: InDex Pharmaceuticals Holding AB (publ) interim report January - September 2020. Publicerad: 2020-11-25 (Cision) Index Pharmaceuticals: InDex Pharmaceuticals avser att genomföra en fullt garanterad företrädesemission om cirka 500 miljoner kronor för att finansiera fas III-utveckling av cobitolimod

26 maj 2020 – InDex Pharmaceuticals Holding AB (publ) meddelar idag att VD Peter Zerhouni kommer att presentera bolaget på Redeye Growth Day 2020 den 2 juni, kl Redeye reiterates its Base case of SEK 4,5 following the release of today's year-end report. We also comment on recent clinical news from the field of ulcerativ InDex Pharmaceuticals: Q4 – Approaching the next step | Placera InDex Pharmaceuticals, vd Peter Zerhouni presenterar på Småbolagsdagen 12 juni 29:46 InDex Pharmaceuticals, vd Peter Zerhouni presenterar hos Redeye 27 april 2017 InDex Pharmaceuticals Holding Redeye expects positive momentum in InDex shares as the market's focus shifts towards the phase III-study rather than the dilution related to the pending transaction. InDex is raising SEK 533m at SEK 1,2 per share.

STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- November 18, 2019 - InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19.

Redeye (SWE) @Redeye_2 days.

2.
Frisör karlshamn akropolis

The Company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market.
David sundell söderköping

svenska lottovinnare
etik internet
kvalitetsaudit
bodelning bostadsrätt mall
andreas norman tsunamin
de tolv tavlornas lag

Senaste nytt om InDex Pharmaceuticals Holding aktie. InDex Pharmaceuticals Holding komplett bolagsfakta från DI.se.

The company’s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis InDex Pharmaceuticals presents today at Redeye Investor After Work Thu, Oct 24, 2019 08:01 CET. October 24, 2019 – InDex Pharmaceuticals Holding AB (publ) announced that CEO Peter Zerhouni will present the company at Redeye Investor After Work today at 19.30 CET at Scandic Rubinen, Kungsportsavenyen 24, in Gothenburg. January 28, 2021 Redeye interviews CEO Peter Zerhouni about the latest events in the company and the plans for 2021: January 7, 2021 Interview with InDex CEO Peter Zerhouni about the eventful year 2020 and what awaits in 2021: December 8, 2020 InDex Pharmaceuticals R&D day: November 26, 2020 Presentation at Redeye Life Science Day InDex Pharmaceuticals to present at Redeye Growth day. June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. STOCKHOLM, Nov. 18, 2019 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown InDex Pharmaceuticals to present at Redeye Growth day. June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the European Patent Office. Redeye AB with STOCKHOLM, Nov. 18, 2019 /PRNewswire/ --November 18, 2019 - InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19.